LINK WILLIAM J PHD sold $776K of TARS

LINK WILLIAM J PHD sold 12,500 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $62.12 ($61.97–$62.94, $0.78M total) across 2 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LINK WILLIAM J PHD
Published Jun 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Neutral
high confidence
Mentioned
$TARS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSNeutralLow
01

Why it matters

A director’s open-market sale under a pre-arranged 10b5-1 plan typically has limited informational value for near-term valuation, absent other company-specific developments.

02

Market read

Traders may note the insider selling signal, but the 10b5-1 framing reduces the likelihood of a meaningful fundamental repricing.

03

What to watch

The filing does not state motivations, and the net effect depends on whether other insiders or the company have concurrent buybacks or news not mentioned here.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-17, covering sales dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Tarsus Pharmaceuticals, Inc.

Company-level read

Ticker impact

$TARSNeutralHigh confidence
Context

Tarsus Pharmaceuticals director William J Link sold 12,500 shares in open-market transactions under a 10b5-1 plan, totaling about $776.5K.

Expected impact

Limited near-term impact expected; any reaction is likely muted given the 10b5-1 structure.

Evidence & confidence

Form 4 details a director’s planned open-market sale with no accompanying company-specific news, guidance, or operational change.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Tarsus Pharmaceuticals, Inc.

    Subject of the Form 4 insider sale disclosure.

  • William J Link, PhD

    Director who sold 12,500 shares across two trades on 2026-06-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.